QB3 Webinar: Sonja Schrepfer, Sana Biotechnology. “The Future of Stem Cell Therapy: Hypoimmune Cell Products”
Induced pluripotent stem cells (iPSCs) hold great potential as therapies to repair damaged tissue or replace cell types missing due to genetic defects. However, even iPSCs derived from a patient can mutate in culture, causing immune rejection when they are re-transplanted. Being able to control immune rejection is key to using iPSCs as theraputics. The...